{'fraction_non_alphanumeric': 0.041935483870967745, 'fraction_numerical': 0.021505376344086023, 'mean_word_length': 5.556338028169014, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Human Umbilical Vein Endothelial Cells Synthesize Functional C3, C5, C6, C8 and C9 In Vitro

Human endothelial cells (EC), cultured serum‐free, synthesize de novo protein which increasingly bind to agarose beads (an alternative pathway activator), until a plateau phase is reached after 24–48 h. EC synthesize functional C3, C5, C6, C8 and C9, which were detected on co‐cultured agarose beads, using relevant polyclonal anti‐complement antibodies. Two monoclonal anti‐C9 neoepitope antibodies (aEl 1, poly C9‐MA) bound to the co‐cultured beads, showing that the terminal complement complex (TCC) (C5b‐9) was assembled on the beads. This also suggests that C7 is synthesized. There seems to be a positive correlation between the amount of agarose‐bound labelled protein and agarose‐bound complement. The results indicate that EC produce and secrete the components for the functional alternative and terminal pathways of complement.